Geron begins enrollment in Phase 3 refractory myelofibrosis trial


Geron (NASDAQ:GERN) reported that its Phase 3 IMpactMF clinical trial, which is evaluating imetelstat for the treatment of refractory myelofibrosis, is open for patient screening and enrollment.

The trial is designed to compare imetelstat, a telomerase inhibitor, with the best available therapy in some 320 patients with intermediate-2 or high-risk myelofibrosis. The trial’s primary efficacy endpoint is overall survival.

“As Geron’s second registration-enabling Phase 3 trial in hematologic myeloid malignancies, the IMpactMF trial represents a milestone for our company,” Aleksandra Rizo, M.D., Ph.D., Geron’s CMO, said in a statement.

“The IMpactMF trial will evaluate imetelstat in a poor-prognosis refractory myelofibrosis patient population to confirm the clinical benefits of extended overall survival and symptom improvement observed in our IMbark Phase 2 trial, as well as the reductions in abnormal clones and mutation burden demonstrating disease-modifying activity of imetelstat,” she added.

Geron expects the majority of its planned 150 global clinical trial sites to be open for screening and enrollment in 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.